Abstracts Archive - Page 1475 of 2607 - ACR Meeting Abstracts

Abstract Number: 1316 • 2017 ACR/ARHP Annual Meeting
Risk of Preterm Delivery Associated with Perinatal Exposure to Dmards in Women with Inflammatory Arthritis: A Population-Based Cohort Study
Nicole W. Tsao^1,2, Eric C. Sayre², Mohsen Sadatsafavi¹, J. Antonio Avina-Zubieta^2,3, Stephanie Ensworth⁴ and Mary A. De Vera^1,2, ¹Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ⁴University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Given the limited data on impacts of perinatal medication use, our objective was to investigate the association between conventional synthetic DMARD (csDMARD) use preconception…
Abstract Number: 1317 • 2017 ACR/ARHP Annual Meeting
Obstetric Outcomes in Women with Rheumatoid Arthritis: Results from Nationwide Inpatient Sample Database 2003-2011
Shweta Kishore¹, Varun Mittal², Venkataraman Palabindala³, Shradha Ahuja³ and Vikas Majithia^1,4, ¹Division of Rheumatology, University of Mississippi, Jackson, MS, ²Division of Hematology and Oncology, Albert Einstein Healthcare Network, Philadelphia, PA, ³Division of Hospital Medicine, University of Mississippi, Jackson, MS, ⁴Jackson VA Medical Center and University of Mississippi, Jackson, MS
Background/Purpose: Fertility is reduced in patients with Rheumatoid Arthritis (RA) due to unknown cause. Few studies mostly involving single center cohorts have addressed pregnancy outcomes…
Abstract Number: 1318 • 2017 ACR/ARHP Annual Meeting
Abnormal Cerviovaginal Cytology in Adolescents with Systemic Lupus Erythematosus: A Retrospective Case Series
Jennifer Kurkowski¹, Martha Curry², Marietta deGuzman³, Jane Geyer⁴ and Oluyemisi Adeyemi-Fowode⁵, ¹Department of Obstetrics and Gynecology, Baylor College of Medicine, Texas Childrens Hospital, Houston, TX, ²Pediatric rheumatology, Baylor College of Medicine and Texas Childrens Hospital, Houston, TX, ³Baylor College of Medicine, Division of Pediatric Rheumatology, Houston, TX, ⁴Baylor College of Medicine, Division of Pediatric and Adolescent Gynecology, Houston, TX, ⁵Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Childrens Hospital, Houston, TX
Background/Purpose: Guidelines recommend screening for cervical cancer in women starting at age 21 but according to the American Congress of Obstetricians and Gynecologists, exceptions should…
Abstract Number: 1319 • 2017 ACR/ARHP Annual Meeting
TAS05567 Is a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor That Attenuates Disease Severity in Animal Models of Autoimmune Diseases
Hiroaki Hayashi, Ryuusuke Kaneko, Manabu Tayama, Shunsuke Demizu, Daichi Akasaka, Hiroki Irie, Aki Kawagishi, Yoshio Ogino, Teruhiro Utsugi, Eiji Sasaki and Yoshikazu Iwasawa, TAIHO PHARMACEUTICAL CO., LTD., Tsukuba, Japan
Background/Purpose: Spleen tyrosine kinase (Syk) is a non-receptor cytoplasmic tyrosine kinase. B-cell receptor (BCR) and Fc receptor-mediated syk signaling pathways lead to activation of several…
Abstract Number: 1320 • 2017 ACR/ARHP Annual Meeting
TAS5315, a Novel Bruton’s Tyrosine Kinase Inhibitor, Ameliorates Inflammation and Bone Erosion in Murine Model for Rheumatoid Arthritis
Yohei Yoshiga¹, Fumihito Hosoi¹, Satoru Iguchi¹, Ryuusuke Kaneko², Yoshinori Nakachi¹, Daichi Akasaka², Kenji Tanaka², Kazuhiko Yonekura², Teruhiro Utsugi², Eiji Sasaki² and Yoshikazu Iwasawa², ¹TAIHO PHARMACEUTICAL CO., LTD., TSUKUBA, Japan, ²TAIHO PHARMACEUTICAL CO., LTD., Tsukuba, Japan
Background/Purpose: The erosions of bone and cartilage are a cardinal feature of rheumatoid arthritis (RA) and associated with disease severity and poor functional outcome. Although…
Abstract Number: 1321 • 2017 ACR/ARHP Annual Meeting
Inhibition of the Mechanistic Target of Rapamycin Pathway and Glutaminolysis Facilitates the Expansion of Myeloid-Derived Suppressor Cells and Synergistically Ameliorates Arthritis in SKG Mice
Yo Ueda¹, Takaichi Okano¹, Hirotaka Yamada¹, Yoshihide Ichise¹, Ikuko Naka², Soshi Takahashi³, Sho Sendo⁴, Kengo Akashi², Akira Onishi⁵, Jun Saegusa⁴ and Akio Morinobu³, ¹Department of Rheumatology and Clinical immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Kobe University Graduate School of Medicine, Kobe, Japan, ³Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁴Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁵Rheumaology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature cells that increase in the pathological state such as tumor or inflammation and have…
Abstract Number: 1322 • 2017 ACR/ARHP Annual Meeting
Tissue Folate Dysregulation Is Associated with Disease Activity and Methotrexate Response in Collagen-Induced Arthritis
Leon van Haandel¹, Rakesh Singh², Paul Kiptoo³, Teruna Siahaan³, Mara L Becker⁴ and Ryan Funk⁵, ¹2401 Gillham Road, Children's Mercy, Kansas City, MO, ²Department of Pharmacy Practice, University of Kansas Medical Center, Kansas City, KS, ³Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, ⁴Rheumatology, Children's Mercy Kansas City, Kansas City, MO, ⁵University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Methotrexate (MTX) is an anti-metabolite inhibitor of folate-dependent biochemical pathways and is effective in reducing disease activity in autoimmune arthritis. This work seeks to…
Abstract Number: 1323 • 2017 ACR/ARHP Annual Meeting
Crucial Roles for Toll-like Receptor 9 in the Pathogenesis of Erosive Autoimmune Arthritis and during Osteoclastogenesis
Anita Fischer¹, Brigitte Meyer¹, Birgit Niederreiter², Erik Lönnblom³, Rikard Holmdahl⁴ and Günter Steiner², ¹Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²Rheumatology, Medical University of Vienna, Vienna, Austria, ³Department of Medical Biochemistry & Biophysics, Karolinska Institute, Stockholm, Sweden, ⁴Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Release and insufficient removal of endogenous nucleic acids may be involved in triggering harmful autoimmune reactions important in the initiation of systemic autoimmune diseases…
Abstract Number: 1324 • 2017 ACR/ARHP Annual Meeting
Angiotensin II Type I Receptor Deficiency Exacerbates Erosive Bone Destruction of hTNF-Transgenic Arthritis Mice
Takafumi Mito¹, Tomoyuki Mukai¹, Shunichi Fujita¹, Shoko Kodama¹, Akiko Nagasu¹, Teruki Sone² and Yoshitaka Morita¹, ¹Department of Rheumatology, Kawasaki Medical School, Kurashiki, Okayama, Japan, ²Department of Nuclear Medicine, Kawasaki Medical School, Kurashiki, Okayama, Japan
Background/Purpose: Angiotensin II (Ang II) is known to function on various organs including kidneys, adrenal glands as well as the nervous and cardiovascular systems through…
Abstract Number: 1325 • 2017 ACR/ARHP Annual Meeting
Immune Responses to Peptides Containing Homocitrulline or Citrulline in the DR4-Transgenic Mouse Model of Rheumatoid Arthritis
Patrick Lac¹, Sheri Saunders¹, Elena Tutunea-Fatan¹, Lillian Barra², David Bell³ and Ewa Cairns², ¹Microbiology and Immunology, The University of Western Ontario, London, ON, Canada, ²Medicine, Microbiology and Immunology, The University of Western Ontario, London, ON, Canada, ³Medicine, The University of Western Ontario, London, ON, Canada
Background/Purpose: Antibodies to proteins/peptides containing citrulline (commonly measured using cyclic citrullinated peptide, CCP2) are hallmarks of Rheumatoid Arthritis (RA). These antibodies are strongly associated with…
Abstract Number: 1326 • 2017 ACR/ARHP Annual Meeting
Alpha-Glucosidase Inhibitors Alter Gut Microbiota and Ameliorate Collagen-Induced Arthritis
Lingshu Zhang^1,2, Pingfang Song², Xiaowei Zhang², Christina Metea², Matthew Schleisman², Lisa Karstens², Eric Leung², Jun Zhang³, Qiang Xu^2,4, Yi Liu⁵, Mark Asquith² and Cong-Qiu Chu^6,7, ¹Department of Rheumatology, West China Hospital, Sichuan University, Chengdu, China, ²Oregon Health & Science University, Portland, OR, ³MD Anderson Cancer Center, Houston, TX, ⁴Guangzhou University of Chinese Medicine, Guangzhou, China, ⁵Department of Rheumatology and Immunology, West China Hospital of Sichuan University, Chengdu, China, ⁶Rheumatology, Oregon Health & Science University, Portland, OR, ⁷Rheumatology, VA Portland Health Care System, Portland, OR
Background/Purpose: Acarbose, an alpha-glucosidase inhibitor anti-diabetic drug exhibited anti-arthritic effects. The mechanism that acarbose exerts its anti-arthritic effects is not fully understood. Since > 90%…
Abstract Number: 1327 • 2017 ACR/ARHP Annual Meeting
Decreased Inflammatory Arthritis in Human Serum Paraoxonase 1 Transgenic Mice
Christina Charles-Schoeman¹, Ani Shahbazian², Jennifer Wang³, Victor Grijalva⁴ and Srinivasa T. Reddy⁴, ¹University of California, Los Angeles, Los Angeles, CA, ²Medicine-Rheumatology, University of California, Los Angeles, Los Angeles, CA, ³UCLA, Los Angeles, CA, ⁴Medicine-Cardiology, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Paraoxonase 1 (PON1) is an HDL-associated protein, which hydrolyzes biologically active oxidized phospholipids and prevents oxidation of lipids in LDL and HDL. Increased lipid…
Abstract Number: 1328 • 2017 ACR/ARHP Annual Meeting
A Dual ICOS/CD28 Antagonist ICOSL Variant Ig Domain (vIgDTM) Potently Suppresses Mouse Collagen-Induced Arthritis and Human Xenograft Graft Vs. Host Disease (GvHD)
Stacey Dillon¹, Katherine Lewis¹, Ryan Swanson², Lawrence Evans², Michael Kornacker³, Steve Levin², Martin Wolfson⁴, Erika Rickel², Susan Bort², Sherri Mudri¹, Aaron Moss¹, Michelle Seaberg¹, Janhavi Bhandari⁴, Sean MacNeil⁴, Joe Hoover⁴, Mark Rixon⁴ and Stanford Peng⁵, ¹Translational Sciences, Alpine Immune Sciences, Seattle, WA, ²Immunology, Alpine Immune Sciences, Seattle, WA, ³Protein Engineering, Alpine Immune Sciences, Seattle, WA, ⁴Protein Therapeutics, Alpine Immune Sciences, Seattle, WA, ⁵Clinical, R&D, Alpine Immune Sciences, Seattle, WA
Background/Purpose: Our proprietary variant Ig domain (vIgD) platform creates novel, therapeutically-applicable protein domains with tailored specificity and affinity. These vIgDs are created through directed…
Abstract Number: 1329 • 2017 ACR/ARHP Annual Meeting
A Quantitative Framework for Evaluating Drug Combination Treatment in Rat Collagen-Induced-Arthritis Model
Amy Meng¹, Julie Di Paolo², Shringi Sharma³ and Anita Mathias³, ¹Clinical Pharmacology, Gilead Sciences, Foster City, CA, ²Immunology and Inflammation Biology, Gilead Sciences, Foster City, CA, ³Gilead Sciences, Foster City, CA
Background/Purpose: Filgotinib (FIL), a JAK1 inhibitor, and GS-9876, a SYK inhibitor, are currently being evaluated as once-daily monotherapy in subjects with rheumatoid arthritis (RA). A…
Abstract Number: 1330 • 2017 ACR/ARHP Annual Meeting
Rhesus Theta Defensin 1 (RTD-1) Suppresses Disease-Associated Genes and Induces Anti-Inflammatory Expression Signature in Synovial Tissues of Rat Model of Rheumatoid Arthritis
Prasad Tongaonkar¹, Vasu Punj², Akshay Subramanian³, Dat Tran³, Katie Trinh⁴, Justin Schaal¹, Percio S. Gulko⁵, Andre Oullette³ and Michael Selsted³, ¹Pathology and Laboratory Medicine, Keck School of Medicine University of Southern California, Los Angeles, CA, ²Medicine, Keck School of Medicine University of Southern California, Los Angeles, CA, ³Keck School of Medicine University of Southern California, Los Angeles, CA, ⁴Pathology, Keck School of Medicine University of Southern California, Los Angeles, CA, ⁵Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Theta (θ) defensins are the only known macrocyclic peptides found in the Animal kingdom and are exclusively expressed in Old World monkeys. θ-defensins were…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].